Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Nerve Growth Factor (Cerebrolysin®) for Treatment of Neonatal Hypoxic Ischemic Encephalopathy

NCT01059461 is registered in ClinicalTrials.gov with Sahar M.A. Hassanein, MD as lead sponsor.

NCT NCT01059461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01059461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Nerve Growth Factor (Cerebrolysin®) for Treatment of Neonatal Hypoxic Ischemic Encephalopathy
Lead sponsor
Sahar M.A. Hassanein, MD
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2011
Completion date
September 30, 2013
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hypoxic-ischemic encephalopathy